BOSTON--(BUSINESS WIRE)--Apr 29, 2024--
CLEW, a clinical intelligence and predictive surveillance company, today announced the general availability of its FDA-cleared, AI-driven, intelligent clinical surveillance platform. Built upon proprietary, machine-learning derived prediction models and rules-based best practices, the CLEW platform offers health systems an early identification of a patient’s risk of deterioration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429304093/en/
(Photo: CLEW)
CLEW initially introduced its system of AI-generated prediction models in 2019 to support critical care and telemedicine operations, aiming to enhance patient care in virtual intensive care units (VICUs or Tele-ICUs). Implemented in numerous critical care departments across the United States, including Penn State Health, the system quickly demonstrated its efficacy and CLEW promptly responded to customer demands by expanding its platform to areas such as the emergency department, medical/surgical floors, perioperative suites, and specialty care units.
“As we navigate the complexities of modern healthcare, AI-derived systems emerge as a beacon of innovation, transforming our approach to care delivery,” Paul Roscoe, CLEW CEO shared. “When delivered with meticulous regulatory oversight, AI can unlock new possibilities for precision medicine, early detection, and personalized treatments. Our commitment to integrating AI-driven prediction models into healthcare reflects our dedication to enhancing patient outcomes, driving efficiencies, and ultimately, saving lives.”
Equipped with these advanced clinical insights, caregivers can focus on delivering exceptional patient care at the highest level of their licensure. The CLEW system empowers care teams to intervene proactively in identifying high-risk patients up to eight hours before physiological signs and other monitoring systems would indicate. This leads to lower mortality rates, decreased complications, and fewer readmissions. As a result, proactive and timely care mitigates unforeseen bottlenecks, reduces length of stay and improves overall capacity.
In addition to CLEW’s robust prediction models, its platform includes built-in, best practice clinical protocols. They are easily customizable, allowing health systems to add their own standard practices for consistent deployment of specific care plans. With its NotifyMe solution, caregivers can receive tailored multi-parameter smart alerts, specifically designed to pinpoint urgent and complex clinical scenarios. Clinicians have the flexibility to determine which attributes and clinical criteria are crucial for monitoring and personalize the configuration.
The CLEW platform also includes prediction-driven clinician-centric tools designed to reduce nursing fatigue, including a real-time, priority-driven patient worklist developed in collaboration with nurses at Penn State Health. Since going live with the platform, the critical care team at Penn State has integrated the use of CLEW into their daily workflow.
A recent peer-reviewed study published in CHEST Journal , notably found that predictions from the CLEW platform were at least five times more accurate than alerts from the leading telemedicine system and generated 50 times fewer alarms than other monitoring systems. For more information about that study, click here.
For more information about the CLEW system, contact the CLEW team.
About CLEW Medical, Inc.
CLEW offers the first FDA-cleared, class II medical device, AI-based clinical predictive models for critical care as a part of its intelligent clinical surveillance platform. Its ability to offer accurate, predictive insights around patient deterioration allows health systems to optimize patient interventions, decreasing mortality and reducing complications & readmissions. Its proprietary models offer an optimal balance of precision and sensitivity, which results in fewer high-risk notifications, reducing alarm fatigue amongst providers and clinicians. For more information, visit clewmed.com.
CLEW offers the first FDA-cleared, class II medical device, AI-based clinical predictive models for critical care as a part of its intelligent clinical surveillance platform. Its ability to offer accurate, predictive insights around patient deterioration allows health systems to optimize patient interventions, decreasing mortality and reducing complications & readmissions. Its proprietary models offer an optimal balance of precision and sensitivity, which results in fewer high-risk notifications, reducing alarm fatigue amongst providers and clinicians. For more information, visit clewmed.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20240429304093/en/
CONTACT: Media
Matter Health for CLEW Medical
Matt Robbins
T: 617.874.5203
clew@matternow.com
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: TECHNOLOGY FDA CLINICAL TRIALS TELEMEDICINE/VIRTUAL MEDICINE SOFTWARE BIOTECHNOLOGY HEALTH GENERAL HEALTH ARTIFICIAL INTELLIGENCE
SOURCE: CLEW Medical, Inc.
PUB: 04/29/2024 08:30 AM/DISC: 04/29/2024 08:32 AM
http://www.businesswire.com/news/home/20240429304093/en
Most Popular
Comments / 0